| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 46.20 | 1.3% | 115.1% |
| Total Income | 47.07 | 0.9% | 89.5% |
| Expenditure | 46.79 | 3.9% | 62.8% |
| PBT | 0.28 | 88.7% | 107.1% |
| Net Profit | 0.20 | 89.0% | 104.2% |
| OPM | 0.17% | 4.95pp | 36.44pp |
| NPM | 0.43% | 3.41pp | 19.52pp |
| EPS | 0.04 | 90.5% | 103.7% |
Valiant Laboratories Ltd Announces Q2 and H1 FY2025 Results with 15% YoY Revenue Growth
11 Nov 2025 · 11 Nov 2025, 05:09 pm
Summary
Valiant Laboratories Ltd has announced its Q2 and H1 FY2025 results with a 15% YoY revenue growth. The company's Board of Directors approved the Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025.
Key Highlights
- 1
Q2 and H1 FY2025 Results
- 2
15% YoY revenue growth
- 3
Audited Standalone and Consolidated Financial Results
- 4
Results approved by the Board of Directors
- 5
Valiant Laboratories Ltd
Management Comments
Valiant Laboratories Ltd
The company's financial results for the quarter ended 30 September 2025 and year to date results for the period 1 April 2025 to 30 September 2025 are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ‘Interim Financial Reporting’.
Raman S. Shah & Co.
Chartered Accountants
We have audited the accompanying standalone financial results of Valiant Laboratories Limited and in our opinion, these financial results give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ‘Interim Financial Reporting’.
Informational and educational content only. Not investment advice.